ALGS
NASDAQ HealthcareAligos Therapeutics, Inc. - Common stock
Biotechnology
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
�� 市场数据
| 价格 | $6.68 |
|---|---|
| 成交量 | 815,287 |
| 市值 | 41.33M |
| 贝塔系数 | 2.620 |
| RSI（14日） | 50.2 |
| 200日均线 | $8.69 |
| 50日均线 | $7.25 |
| 52周最高 | $13.69 |
| 52周最低 | $4.20 |
| Forward P/E | -1.25 |
| Price / Book | 0.77 |
🎯 投资策略评分
ALGS 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (98/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 💰 Dividend Daddy (2/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ALGS in your text
粘贴任何文章、记录或帖子 — 工具将提取 ALGS 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.